SCHEMBL23303121

SCHEMBL23303121

CC(C)(C)[Si](C)(C)OCCc1ccc(NC(=O)O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
HPGD P15428 2/20 0.43
PPARA Q07869 5/20 0.42
NR1H4 Q96RI1 2/20 0.40
TP53 P04637 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
GAA P10253 1/20 0.40
KLK7 P49862 1/20 0.40
ALDH1A1 P00352 1/20 0.39
MEN1 O00255 1/20 0.39
CASP3 P42574 1/20 0.39
KMT2A Q03164 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
POLB P06746 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24853890 0.87 NPC1 (0.46) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
SCHEMBL19306519 0.85 KLK7 (0.41) NPC1RAB9AHPGDNR1H4TP53
SCHEMBL17064260 0.82 TRPV1 (0.57) NPC1RAB9ASMN1; SMN2GAAALDH1A1
SCHEMBL30643687 0.81 RAB9A (0.38) NPC1RAB9ASMN1; SMN2GAAALDH1A1
SCHEMBL20607583 0.81 AR (0.35) NPC1RAB9APPARAALDH1A1MEN1
SCHEMBL4741957 0.81 ALDH1A1 (0.44) HPGDNR1H4ALDH1A1MEN1KMT2A
SCHEMBL17361911 0.80 APP (0.35) PPARA
SCHEMBL17064253 0.79 HDAC3 (0.47) NPC1RAB9AHPGDSMN1; SMN2GAA
SCHEMBL16245932 0.78 RAB9A (0.47) NPC1RAB9AHPGDTP53SMN1; SMN2
SCHEMBL2696466 0.78 CYP1A2 (0.41) NPC1RAB9APPARASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002367-A1 BIFUNCTIONAL COMPOUNDS C4 THERAPEUTICS, INC. 2023-01-05 US disclosed
EP-4054724-A1 BIFUNCTIONAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2022-09-14 EP disclosed
WO-2021086785-A1 BIFUNCTIONAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2021-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002367-A1 BIFUNCTIONAL COMPOUNDS ITCH, EGFR, MUC1 NPC1 725/4885RAB9A 281/4885HPGD 3888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.